ADPriOMICS: priorització de les vies que relacionen l’envelliment i la malaltia d’Alzheimer amb la deterioració cognitiva i la demència

ADPriOMICS is a collaborative research initiative within the framework of the JPND programme (EU Joint Programme – Neurodegenerative Disease Research), whose primary objective is to prioritise the biological pathways that link ageing to Alzheimer’s disease and their impact on cognitive decline and dementia.

The project focuses on inflammation as a key process explaining the brain’s vulnerability to ageing and neurodegeneration. Through the analysis of genomic, gene expression, proteomic data and deep phenotyping of patients from memory clinics, ADPriOMICS aims to discover and validate new therapeutic targets and predictive biomarkers for Alzheimer’s disease.

Ace Alzheimer Center plays a key role within the consortium as a leading reference in genetics. Under the leadership of Dr Fernández, the team will process more than 3,000 whole-genome sequencing (WGS) samples to identify genes, biological pathways and molecular signatures involved in the relationship between ageing, inflammation and Alzheimer’s disease.

The consortium brings together experts from Germany, France, the Netherlands, Spain, Luxembourg and the Czech Republic, and collaborates with centres in Denmark, Finland and Belgium. With funding of more than €1.8 million and a duration of three years, ADPriOMICS aims to translate scientific knowledge into diagnostic and therapeutic opportunities that can improve the lives of millions of people affected by Alzheimer’s disease.